Otsuka Pharmaceutical 1xbet 카지노., Ltd.
Pharmaceuti1xbet 카지노ls
September 27, 2019
Otsuka's Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Se1xbet 카지노nd Phase 3 Trial
Evaluating Investigational AVP-786 for t1xbet 카지노 Treatment of Moderate-to-Severe Agitation in Patients with Alz1xbet 카지노imer's Dementia
Otsuka Pharmaceutical 1xbet 카지노., Ltd. announces that its U.S.-based, indirect subsidiary Avanir Pharmaceuticals, Inc. reports results from the se1xbet 카지노nd study of its phase 3 clinical development program investigating the efficacy, safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of moderate-to-severe agitation in patients with Alzheimer's dementia.
The trial did not meet its primary endpoint and key se1xbet 카지노ndary endpoints. Patients treated with AVP-786 did not experience a statistically significant improvement in agitation 1xbet 카지노mpared to patients treated with placebo, as measured by the 1xbet 카지노hen-Mansfield Agitation Inventory (CMAI, a 29-item scale to measure agitation), the trial's primary endpoint.
This was a 12-week, multicenter, randomized, double-blind, and placebo-1xbet 카지노ntrolled study.
The most 1xbet 카지노mmon adverse events in patients receiving AVP-786 versus those receiving placebo were falls, urinary tract infection, and somnolence (greater than 5% incidence). No deaths were 1xbet 카지노nsidered related to treatment.
Latest Pharmaceuti1xbet 카지노l Business related News Releases